Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (Melanoma) and HT29 cell lines

Authors
Okada, Y Tsuda, Y Wanaka, K Tada, M Okamoto, U Okamoto, S Hijikata-Okunomiya, A Bokonyi, G Szende, B Keri, G
Citation
Y. Okada et al., Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (Melanoma) and HT29 cell lines, BIOORG MED, 10(19), 2000, pp. 2217-2221
Citations number
13
Categorie Soggetti
Chemistry & Analysis
Journal title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
ISSN journal
0960894X → ACNP
Volume
10
Issue
19
Year of publication
2000
Pages
2217 - 2221
Database
ISI
SICI code
0960-894X(20001002)10:19<2217:DOPAPK>2.0.ZU;2-2
Abstract
trans-4-Aminomethylcyclohexanecarbonyl-Tyr(O-Pic)-octylamide (YO-2) inhibit ed plasmin (PL) selectively, while trans-4-aminomethylcyclohexanecarbonyl-P he-4-carboxymethylanilide (YO-1) inhibited plasma kallikrein (PK). YO-2 ind uced apoptosis of M1 (melanoma) cell line and HT29 colon carcinoma cells du ring 24 h through activation of caspase-3, while YO-1 did not affect either cell line even during 48 h. (C) 2000 Elsevier Science Ltd. All rights rese rved.